Lv43
760 积分 2024-09-18 加入
Identifying Lipid Metabolism‐Related Therapeutic Targets and Diagnostic Markers for Lung Adenocarcinoma by Mendelian Randomization and Machine Learning Analysis
23天前
已完结
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
26天前
已完结
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
1个月前
已完结
Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma
1个月前
已完结
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
1个月前
已完结
LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial
2个月前
已完结
Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer
2个月前
已完结
A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment
2个月前
已完结
Top advances of the year: Targeted therapy for lung cancer
2个月前
已完结
Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials
2个月前
已完结
皖公网安备34019202002308
